A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

GENERIC NAME 
Rabeprazole Pantoprazole will be automatically substituted for other proton pump inhibitors. When administering PPIs  via feeding tubes auto substitute Lansoprazole Solutabs.

        Pantoprazole (Protonix), injection and oral, is the proton pump inhibitor of choice, with automatic substitution for omeprazole (Prilosec), rabeprazole (Aciphex),  Lansoprazole (Prevacid), and other oral proton pump inhibitors unless the physician has checked the dispense as written block.

Dosing Equivalence (mg)

Lansoprazole

(Prevacid)

Esomeprazole

(Nexium)

Omeprazole

(Prilosec)

Rabeprazole

(Aciphex)

Pantoprazole

(Protonix)

30 qd

20 qd

20 qd

20 qd

20 qd

30 qd

40 qd

40 qd

20 qd

40 qd

30 bid

20-40 bid

20-40 bid

20 bid

40 bid

Lanoprazole Solutabs, 15 mg or 30 mg, may be mixed with water and placed down a very small bore pediatric feeding tube. The granules do not clump or adhere to the tube.

Lanoprazole

Omeprazole

1-11 years

<= 30 kg

15 mg qd

>= 2 years

< 20 kg

10 mg qd

 

> 30 kg

30 mg qd

 

>=20 kg

20 mg qd

12-17 years

Non erosive GERD

15 mg qd

 

 

 

 

Erosive GERD

30 mg qd

 

 

 

Pantoprazole IV Criteria for use

        Criteria for use of IV Proton Pump Inhibitors (PPIs) are list below.  If a patient does not meet criteria the pharmacist will call the physician and/or leave a chart note recommending conversion to oral therapy.

  • Initial treatment of patients with active upper GI tract bleeding, until they can tolerate oral therapy, usually after three days of therapy.
  • Initial treatment of patients with Zollinger-Ellison syndrome, until they can tolerate oral therapy
  • Stress-ulcer prophylaxis for critical care patients
  • Patients who require PPI therapy who can not tolerate oral or NG PPI therapy

        Patients on IV proton pump inhibitors will have an order entered for the oral route allowing the nurse to use the oral route when the patient is tolerating oral therapy. Proton pump inhibitors may be given by the oral route if the patient does not have active gastrointestinal bleeding, malabsorption syndrome, short bowel syndrome, severe diarrhea, uncontrolled nausea and vomiting, continuous nasogastric suctioning, and is not at risk for aspiration. 

 

Ranitidine Autosubstitution with Famotidine

    Famotidine, the P&T preferred H2 antagonist, will be automatically substituted for ranitidine, cimetidine, nizatidine, other H2 when ordered by the IV or oral route unless the physician has checked the dispense as written block or the patient is allergic to famotidine.

Dosage Conversion:

Cimetidine                                                         Famotidine

            300 mg q6-8H                                       20 mg q12H

            300 mg q12-24H                                    20 mg q24H

            400 mg QHS                                         20 mg QHS

            400 mg BID                                           10 mg BID or 20 mg QHS

            400 mg QID                                          20 mg BID

            800 mg QHS                                         40 mg QHS

            800 mg BID                                           20 mg BID

Ranitidine

            50 mg q6-8H IV                                     20 mg q12H

            50 mg q12-24H IV                                 20 mg q24H

            150 mg QD                                           20 mg QD

            150 mg BID                                           20 mg q12h

            300 mg QHS                                         40 mg QHS

              

 

Renal Drug Dosing The follow adobe files may be found at the  http://www.nephrologypharmacy.com/ web site

Dialysis of Drugs Text 2006

Peritoneal Dialysis Text 2006

 
Risedronate

Risedronate (Actonelģ) Dosing

Indication

Ordered

Dispense

Crohnís Disease

N/A

N/A

Osteoporosis

(Male Treatment)

35 mg po once weekly

7- 5 mg tablets once weekly

Osteoporosis due to corticosteroids (Treatment)

5 mg po once daily

5 mg po once daily

Osteoporosis due to corticosteroids (Prophylaxis)

5 mg po once daily

5 mg po once daily

Postmenopausal osteoporosis (Treatment)

35 mg po once weekly

OR

75 mg po taken on 2 consecutive days each month

7- 5 mg tablets po once weekly

 

Postmenopausal osteoporosis (Prophylaxis)

35 mg po once weekly

OR

75 mg po taken on 2 consecutive days each month

7- 5 mg tablets po once weekly

Padgetís disease

30 mg po once daily for 2 months

30 mg po once daily for 2 months

Home


Hit Counter